CT screening for lung cancer: update 2005

I-ELCAP investigators; Dorith Shaham

doi:10.1016/j.soc.2005.07.002

CT screening for lung cancer: update 2005

I-ELCAP investigators, Dorith Shaham

Center for Medical Education

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Currently available results on CT screening for lung cancer show that (1) the work-up on baseline screening can be confined to less than 15% of the individuals and to less than 6% on annual repeat screening, (2) almost all cases are detected by screening with very few diagnoses made between screening on the prompting of symptoms, and (3) over 80% of all the diagnoses are of stage I. This diagnostic performance results from following the I-ELCAP regimen of screening which defines a positive result of the initial CT in the regimen as well as the work-up leading to a diagnosis of lung cancer. The diagnostic performance raises prognostic questions as to the genuineness and curability of these screen-diagnosed lung cancers. All diagnoses of malignancy were confirmed by an expert pathology review and found to represent genuine lung cancer as defined by the 2004 World Health Organization pathologic criteria. Estimates based on growth rates suggest that about 90% of the baseline-diagnosed stage I cancers are genuine cancers, as are essentially all of those diagnosed on annual repeat screening. Preliminary results of the curability of genuine screen-diagnosed stage I lung cancers indicate a high curability rate of more than 90%. This suggests that more than a high proportion of deaths from lung cancer can be prevented by CT screening followed by early resection. Using these results, the benefit of a single round of CT screening can be determined for an individual based on the age and smoking history.

Original language	English
Pages (from-to)	761-76
Number of pages	16
Journal	Surgical Oncology Clinics of North America
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2005.07.002
State	Published - Oct 2005

Bibliographical note

Funding Information:
Joan & Sanford I. Weill Medical College of Cornell University, New York, NY: Claudia I. Henschke, Principal Investigator, David F. Yankelevitz, Dorothy I. McCauley Azumi Hospital, Nagano, Japan: Shusuke Sone, Takaomi Hanaoka CBNS, City University of New York at Queens College, Queens, NY: Steven Markowitz, Albert Miller LungenZentrum Hirslanden, Zurich, Switzerland: Karl Klingler, Thomas Scherer, Rolf Inderbitzi H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL: Melvyn Tockman Hadassah Medical Organization, Jerusalem, Israel: Dorith Shaham Clinica Universitaria de Navarra, Pamplona, Spain: Javier Zulueta, Gorka Bastarrika, Maria D. Lozano Swedish Medical Center, Seattle, WA: Kim Rice, Ralph Aye National Cancer Institute Regina Elena, Rome, Italy: Salvatore Giunta, Marcello Crecco, Patrizia Pugliese State University of New York at Stony Brook, Stony Brook, NY: Matthew Rifkin, Eddie S. Fiori Columbia University Medical Center, New York, NY: John H.M. Austin, Gregory D.N. Pearson Maimonides Medical Center, Brooklyn, NY: Samuel Kopel Roswell Park Cancer Institute, Buffalo, NY: Donald Klippenstein, Alan Litwin, Peter A. Loud Christiana Care, Helen F. Graham Cancer Center, Newark, DE: Thomas Bauer, James Lally State University of New York, Upstate Medical Center, Syracuse, NY: Leslie J. Kohman, Ernest M. Scalzetti North Shore-Long Island Jewish Health System, New Hyde Park, NY: Arfa Khan, Rakesh Shah New York University Medical Center, New York, NY: David Naidich, Georgeann McGuinness Georgia Institute for Lung Cancer Research, Atlanta, GA: Michael V. Smith, Hadyn T. Williams, Louis Lovett University of Toronto, Princess Margaret Hospital, Toronto, Canada: Heidi Roberts, Demetris Patsios Mount Sinai School of Medicine, New York, NY: David S. Mendelson Memorial Sloan-Kettering Cancer Center, New York, NY: Robert T. Heelan, Michelle S. Ginsberg Jackson Memorial Hospital, University of Miami, Miami, FL: Robert Thurer Mount Sinai Comprehensive Cancer Center, Miami Beach, FL: Shari-Lynn Odzer New York Medical College, Valhalla, NY: Terence A.S. Matalon Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA: Davood Vafai Our Lady of Mercy Medical Center, Bronx, NY: Peter H. Wiernik The 5 th Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China: Xueguo Liu Karmanos Cancer Institute, Detroit, MI: Harvey Pass, Carmen Indress Dorothy E. Schneider Cancer Center, Mills-Peninsula Health Services, San Mateo, CA: Barry Sheppard Evanston Northwestern Healthcare Medical Group, Evanston, IL: Daniel Ray Greenwich Hospital, Greenwich, CT: David Mullen Sharp Memorial Hospital, San Diego, CA: Michael Kalafer City of Hope National Medical Center, Duarte, CA: Fred Grannis, Arnie Rotter Holy Cross Hospital Cancer Institute, Silver Spring, MD: Frank Sullivan, Marlana Ottinger Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA: Elber Camacho St.Agnes Cancer Center, Baltimore, MD: Enser Cole ProHealth Care Regional Cancer Center, Waukesha and Oconomowoc Memorial Hospitals, Oconomowoc, WI: M. Kristin Thorsen, Richard Hansen

Keywords

Cause of Death
Humans
Lung Neoplasms/diagnostic imaging
Mass Screening/methods
Neoplasm Staging
Prognosis
Smoking/epidemiology
Tomography, X-Ray Computed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.soc.2005.07.002

Cite this

@article{331ceea16a1140698870c11def4de5c9,

title = "CT screening for lung cancer: update 2005",

abstract = "Currently available results on CT screening for lung cancer show that (1) the work-up on baseline screening can be confined to less than 15% of the individuals and to less than 6% on annual repeat screening, (2) almost all cases are detected by screening with very few diagnoses made between screening on the prompting of symptoms, and (3) over 80% of all the diagnoses are of stage I. This diagnostic performance results from following the I-ELCAP regimen of screening which defines a positive result of the initial CT in the regimen as well as the work-up leading to a diagnosis of lung cancer. The diagnostic performance raises prognostic questions as to the genuineness and curability of these screen-diagnosed lung cancers. All diagnoses of malignancy were confirmed by an expert pathology review and found to represent genuine lung cancer as defined by the 2004 World Health Organization pathologic criteria. Estimates based on growth rates suggest that about 90% of the baseline-diagnosed stage I cancers are genuine cancers, as are essentially all of those diagnosed on annual repeat screening. Preliminary results of the curability of genuine screen-diagnosed stage I lung cancers indicate a high curability rate of more than 90%. This suggests that more than a high proportion of deaths from lung cancer can be prevented by CT screening followed by early resection. Using these results, the benefit of a single round of CT screening can be determined for an individual based on the age and smoking history.",

keywords = "Cause of Death, Humans, Lung Neoplasms/diagnostic imaging, Mass Screening/methods, Neoplasm Staging, Prognosis, Smoking/epidemiology, Tomography, X-Ray Computed",

author = "{I-ELCAP investigators} and Henschke, {Claudia I} and Dorith Shaham",

note = "Funding Information: Joan & Sanford I. Weill Medical College of Cornell University, New York, NY: Claudia I. Henschke, Principal Investigator, David F. Yankelevitz, Dorothy I. McCauley Azumi Hospital, Nagano, Japan: Shusuke Sone, Takaomi Hanaoka CBNS, City University of New York at Queens College, Queens, NY: Steven Markowitz, Albert Miller LungenZentrum Hirslanden, Zurich, Switzerland: Karl Klingler, Thomas Scherer, Rolf Inderbitzi H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL: Melvyn Tockman Hadassah Medical Organization, Jerusalem, Israel: Dorith Shaham Clinica Universitaria de Navarra, Pamplona, Spain: Javier Zulueta, Gorka Bastarrika, Maria D. Lozano Swedish Medical Center, Seattle, WA: Kim Rice, Ralph Aye National Cancer Institute Regina Elena, Rome, Italy: Salvatore Giunta, Marcello Crecco, Patrizia Pugliese State University of New York at Stony Brook, Stony Brook, NY: Matthew Rifkin, Eddie S. Fiori Columbia University Medical Center, New York, NY: John H.M. Austin, Gregory D.N. Pearson Maimonides Medical Center, Brooklyn, NY: Samuel Kopel Roswell Park Cancer Institute, Buffalo, NY: Donald Klippenstein, Alan Litwin, Peter A. Loud Christiana Care, Helen F. Graham Cancer Center, Newark, DE: Thomas Bauer, James Lally State University of New York, Upstate Medical Center, Syracuse, NY: Leslie J. Kohman, Ernest M. Scalzetti North Shore-Long Island Jewish Health System, New Hyde Park, NY: Arfa Khan, Rakesh Shah New York University Medical Center, New York, NY: David Naidich, Georgeann McGuinness Georgia Institute for Lung Cancer Research, Atlanta, GA: Michael V. Smith, Hadyn T. Williams, Louis Lovett University of Toronto, Princess Margaret Hospital, Toronto, Canada: Heidi Roberts, Demetris Patsios Mount Sinai School of Medicine, New York, NY: David S. Mendelson Memorial Sloan-Kettering Cancer Center, New York, NY: Robert T. Heelan, Michelle S. Ginsberg Jackson Memorial Hospital, University of Miami, Miami, FL: Robert Thurer Mount Sinai Comprehensive Cancer Center, Miami Beach, FL: Shari-Lynn Odzer New York Medical College, Valhalla, NY: Terence A.S. Matalon Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA: Davood Vafai Our Lady of Mercy Medical Center, Bronx, NY: Peter H. Wiernik The 5 th Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China: Xueguo Liu Karmanos Cancer Institute, Detroit, MI: Harvey Pass, Carmen Indress Dorothy E. Schneider Cancer Center, Mills-Peninsula Health Services, San Mateo, CA: Barry Sheppard Evanston Northwestern Healthcare Medical Group, Evanston, IL: Daniel Ray Greenwich Hospital, Greenwich, CT: David Mullen Sharp Memorial Hospital, San Diego, CA: Michael Kalafer City of Hope National Medical Center, Duarte, CA: Fred Grannis, Arnie Rotter Holy Cross Hospital Cancer Institute, Silver Spring, MD: Frank Sullivan, Marlana Ottinger Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA: Elber Camacho St.Agnes Cancer Center, Baltimore, MD: Enser Cole ProHealth Care Regional Cancer Center, Waukesha and Oconomowoc Memorial Hospitals, Oconomowoc, WI: M. Kristin Thorsen, Richard Hansen ",

year = "2005",

month = oct,

doi = "10.1016/j.soc.2005.07.002",

language = "אנגלית",

volume = "14",

pages = "761--76",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - CT screening for lung cancer

T2 - update 2005

AU - I-ELCAP investigators

AU - Henschke, Claudia I

AU - Shaham, Dorith

N1 - Funding Information: Joan & Sanford I. Weill Medical College of Cornell University, New York, NY: Claudia I. Henschke, Principal Investigator, David F. Yankelevitz, Dorothy I. McCauley Azumi Hospital, Nagano, Japan: Shusuke Sone, Takaomi Hanaoka CBNS, City University of New York at Queens College, Queens, NY: Steven Markowitz, Albert Miller LungenZentrum Hirslanden, Zurich, Switzerland: Karl Klingler, Thomas Scherer, Rolf Inderbitzi H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL: Melvyn Tockman Hadassah Medical Organization, Jerusalem, Israel: Dorith Shaham Clinica Universitaria de Navarra, Pamplona, Spain: Javier Zulueta, Gorka Bastarrika, Maria D. Lozano Swedish Medical Center, Seattle, WA: Kim Rice, Ralph Aye National Cancer Institute Regina Elena, Rome, Italy: Salvatore Giunta, Marcello Crecco, Patrizia Pugliese State University of New York at Stony Brook, Stony Brook, NY: Matthew Rifkin, Eddie S. Fiori Columbia University Medical Center, New York, NY: John H.M. Austin, Gregory D.N. Pearson Maimonides Medical Center, Brooklyn, NY: Samuel Kopel Roswell Park Cancer Institute, Buffalo, NY: Donald Klippenstein, Alan Litwin, Peter A. Loud Christiana Care, Helen F. Graham Cancer Center, Newark, DE: Thomas Bauer, James Lally State University of New York, Upstate Medical Center, Syracuse, NY: Leslie J. Kohman, Ernest M. Scalzetti North Shore-Long Island Jewish Health System, New Hyde Park, NY: Arfa Khan, Rakesh Shah New York University Medical Center, New York, NY: David Naidich, Georgeann McGuinness Georgia Institute for Lung Cancer Research, Atlanta, GA: Michael V. Smith, Hadyn T. Williams, Louis Lovett University of Toronto, Princess Margaret Hospital, Toronto, Canada: Heidi Roberts, Demetris Patsios Mount Sinai School of Medicine, New York, NY: David S. Mendelson Memorial Sloan-Kettering Cancer Center, New York, NY: Robert T. Heelan, Michelle S. Ginsberg Jackson Memorial Hospital, University of Miami, Miami, FL: Robert Thurer Mount Sinai Comprehensive Cancer Center, Miami Beach, FL: Shari-Lynn Odzer New York Medical College, Valhalla, NY: Terence A.S. Matalon Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA: Davood Vafai Our Lady of Mercy Medical Center, Bronx, NY: Peter H. Wiernik The 5 th Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China: Xueguo Liu Karmanos Cancer Institute, Detroit, MI: Harvey Pass, Carmen Indress Dorothy E. Schneider Cancer Center, Mills-Peninsula Health Services, San Mateo, CA: Barry Sheppard Evanston Northwestern Healthcare Medical Group, Evanston, IL: Daniel Ray Greenwich Hospital, Greenwich, CT: David Mullen Sharp Memorial Hospital, San Diego, CA: Michael Kalafer City of Hope National Medical Center, Duarte, CA: Fred Grannis, Arnie Rotter Holy Cross Hospital Cancer Institute, Silver Spring, MD: Frank Sullivan, Marlana Ottinger Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA: Elber Camacho St.Agnes Cancer Center, Baltimore, MD: Enser Cole ProHealth Care Regional Cancer Center, Waukesha and Oconomowoc Memorial Hospitals, Oconomowoc, WI: M. Kristin Thorsen, Richard Hansen

PY - 2005/10

Y1 - 2005/10

N2 - Currently available results on CT screening for lung cancer show that (1) the work-up on baseline screening can be confined to less than 15% of the individuals and to less than 6% on annual repeat screening, (2) almost all cases are detected by screening with very few diagnoses made between screening on the prompting of symptoms, and (3) over 80% of all the diagnoses are of stage I. This diagnostic performance results from following the I-ELCAP regimen of screening which defines a positive result of the initial CT in the regimen as well as the work-up leading to a diagnosis of lung cancer. The diagnostic performance raises prognostic questions as to the genuineness and curability of these screen-diagnosed lung cancers. All diagnoses of malignancy were confirmed by an expert pathology review and found to represent genuine lung cancer as defined by the 2004 World Health Organization pathologic criteria. Estimates based on growth rates suggest that about 90% of the baseline-diagnosed stage I cancers are genuine cancers, as are essentially all of those diagnosed on annual repeat screening. Preliminary results of the curability of genuine screen-diagnosed stage I lung cancers indicate a high curability rate of more than 90%. This suggests that more than a high proportion of deaths from lung cancer can be prevented by CT screening followed by early resection. Using these results, the benefit of a single round of CT screening can be determined for an individual based on the age and smoking history.

AB - Currently available results on CT screening for lung cancer show that (1) the work-up on baseline screening can be confined to less than 15% of the individuals and to less than 6% on annual repeat screening, (2) almost all cases are detected by screening with very few diagnoses made between screening on the prompting of symptoms, and (3) over 80% of all the diagnoses are of stage I. This diagnostic performance results from following the I-ELCAP regimen of screening which defines a positive result of the initial CT in the regimen as well as the work-up leading to a diagnosis of lung cancer. The diagnostic performance raises prognostic questions as to the genuineness and curability of these screen-diagnosed lung cancers. All diagnoses of malignancy were confirmed by an expert pathology review and found to represent genuine lung cancer as defined by the 2004 World Health Organization pathologic criteria. Estimates based on growth rates suggest that about 90% of the baseline-diagnosed stage I cancers are genuine cancers, as are essentially all of those diagnosed on annual repeat screening. Preliminary results of the curability of genuine screen-diagnosed stage I lung cancers indicate a high curability rate of more than 90%. This suggests that more than a high proportion of deaths from lung cancer can be prevented by CT screening followed by early resection. Using these results, the benefit of a single round of CT screening can be determined for an individual based on the age and smoking history.

KW - Cause of Death

KW - Humans

KW - Lung Neoplasms/diagnostic imaging

KW - Mass Screening/methods

KW - Neoplasm Staging

KW - Prognosis

KW - Smoking/epidemiology

KW - Tomography, X-Ray Computed

UR - http://www.scopus.com/inward/record.url?scp=26844505542&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2005.07.002

DO - 10.1016/j.soc.2005.07.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 16226690

SN - 1055-3207

VL - 14

SP - 761

EP - 776

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

CT screening for lung cancer: update 2005

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this